Parallax Volatility Advisers’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $298K | Buy |
+599
| New | +$265K | ﹤0.01% | 1190 |
|
|
2025
Q3 | – | Sell |
-1,046
| Closed | -$466K | – | 1838 |
|
|
2025
Q2 | $466K | Buy |
1,046
+1,043
| +34,767% | +$481K | ﹤0.01% | 1197 |
|
|
2025
Q1 | $1.45K | Sell |
3
-11,260
| -100% | -$5.25M | ﹤0.01% | 1452 |
|
|
2024
Q4 | $4.54M | Buy |
11,263
+3,769
| +50% | +$1.75M | 0.01% | 860 |
|
|
2024
Q3 | $3.49M | Sell |
7,494
-62
| -0.8% | -$29.8K | 0.01% | 939 |
|
|
2024
Q2 | $3.54M | Sell |
7,556
-1,406
| -16% | -$610K | 0.01% | 836 |
|
|
2024
Q1 | $3.75M | Buy |
8,962
+690
| +8% | +$292K | 0.01% | 827 |
|
|
2023
Q4 | $3.37M | Buy |
+8,272
| New | +$3.06M | 0.01% | 979 |
|
|
2023
Q3 | – | Sell |
-60
| Closed | -$21K | – | 2654 |
|
|
2023
Q2 | $21.1K | Sell |
60
-298
| -83% | -$100K | ﹤0.01% | 2136 |
|
|
2023
Q1 | $113K | Buy |
358
+298
| +497% | +$89.4K | ﹤0.01% | 2108 |
|
|
2022
Q4 | $17.3K | Sell |
60
-1,062
| -95% | -$324K | ﹤0.01% | 2503 |
|
|
2022
Q3 | $324K | Buy |
+1,122
| New | +$323K | ﹤0.01% | 2141 |
|
|
2021
Q4 | – | Sell |
-5,024
| Closed | -$977K | – | 3495 |
|
|
2021
Q3 | $911K | Buy |
5,024
+1,491
| +42% | +$291K | ﹤0.01% | 2010 |
|
|
2021
Q2 | $712K | Buy |
3,533
+3,256
| +1,175% | +$681K | ﹤0.01% | 2062 |
|
|
2021
Q1 | $60K | Sell |
277
-32
| -10% | -$7.03K | ﹤0.01% | 2926 |
|
|
2020
Q4 | $73K | Buy |
309
+230
| +291% | +$52.8K | ﹤0.01% | 2998 |
|
|
2020
Q3 | $21K | Sell |
79
-1,470
| -95% | -$406K | ﹤0.01% | 2933 |
|
|
2020
Q2 | $450K | Buy |
1,549
+1,126
| +266% | +$305K | ﹤0.01% | 2009 |
|
|
2020
Q1 | $101K | Sell |
423
-817
| -66% | -$187K | ﹤0.01% | 2141 |
|
|
2019
Q4 | $271K | Sell |
1,240
-1,585
| -56% | -$321K | ﹤0.01% | 1929 |
|
|
2019
Q3 | $479K | Buy |
2,825
+2,824
| +282,400% | +$500K | ﹤0.01% | 1616 |
|
|
2019
Q2 | $0 | Buy |
+1
| New | +$175 | ﹤0.01% | 3851 |
|
|
2019
Q1 | – | Sell |
-3,892
| Closed | -$719K | – | 4154 |
|
|
2018
Q4 | $645K | Buy |
3,892
+3,367
| +641% | +$583K | ﹤0.01% | 1443 |
|
|
2018
Q3 | $101K | Sell |
525
-2,548
| -83% | -$454K | ﹤0.01% | 1724 |
|
|
2018
Q2 | $522K | Buy |
+3,073
| New | +$476K | ﹤0.01% | 1264 |
|
|
2018
Q1 | – | Sell |
-5,920
| Closed | -$887K | – | 4352 |
|
|
2017
Q4 | $887K | Buy |
+5,920
| New | +$877K | ﹤0.01% | 1235 |
|
|
2017
Q2 | – | Sell |
-82,216
| Closed | -$8.99M | – | 4118 |
|
|
2017
Q1 | $8.99M | Buy |
+82,216
| New | +$7.24M | 0.02% | 409 |
|
|
2015
Q4 | – | Sell |
-11,735
| Closed | -$1.22M | – | 4012 |
|
|
2015
Q3 | $1.22M | Buy |
+11,735
| New | +$1.51M | ﹤0.01% | 1217 |
|
|
2015
Q1 | – | Sell |
-3,192
| Closed | -$379K | – | 5652 |
|
|
2014
Q4 | $379K | Buy |
+3,192
| New | +$360K | ﹤0.01% | 2274 |
|
|
2014
Q3 | – | Sell |
-37
| Closed | -$4K | – | 4537 |
|
|
2014
Q2 | $4K | Buy |
+37
| New | +$2.59K | ﹤0.01% | 3911 |
|
Other funds holding VRTX
Parallax Volatility Advisers's VRTX Position: Q2 2026 in Review
Parallax Volatility Advisers opened a new position in Vertex Pharmaceuticals (VRTX) in Q2 2026: 599 shares worth $298K. The stake represents ﹤0.01% of the portfolio and ranks #1190 among its holdings. This is a return to the name: Parallax Volatility Advisers previously reported a position in VRTX as recently as Q2 2025.
Parallax Volatility Advisers first reported a position in VRTX in Q2 2014 and has held it in 30 quarters since. The position peaked at $8.99M in Q1 2017. 1,758 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.
- Parallax Volatility Advisers held 599 shares of Vertex Pharmaceuticals worth $298K as of Q2 2026.
- Vertex Pharmaceuticals was a new Parallax Volatility Advisers position in Q2 2026.
- Vertex Pharmaceuticals made up ﹤0.01% of Parallax Volatility Advisers's portfolio in Q2 2026, its #1190 holding.
- Parallax Volatility Advisers first reported a position in Vertex Pharmaceuticals in Q2 2014 and has held it in 30 quarters since.
- Parallax Volatility Advisers's Vertex Pharmaceuticals position peaked at $8.99M in Q1 2017.
- 1,758 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.
Based on Parallax Volatility Advisers's 13F filing for Q2 2026, filed 14 Aug 2026.